- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07565207
Effect of aiTBS on Intrinsic Spectral Dynamics and Task Performance
The Effect of Within-network aiTBS on Cortical Excitability, Intrinsic Oscillatory Bands, and Behavioral Task Performance
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Study Design. The study design comprises a two-group (DLPFC, TPJ) two-condition (active, sham) parallel design. Order of condition will be counterbalanced across subjects.
Aim 1 Outcome: Spectral Dynamics. All participants will undergo TEP measurements before and after aiTBS therapy (peri-therapeutic) at the left DLPFC and left TPJ to evaluate changes cortical excitability. We will average the results of repeated single pulse stimulation at an intensity of 120% RMT. Participants will also undergo scalp EEG recording during aiTBS sessions and while at rest. Peri-therapeutic oscillatory bands will be determined by averaging responses to across multiple baseline recording sessions using the MATLAB toolbox FieldTrip for detection of signal within the 4-8Hz spectral band. We hypothesize that theta power increases in participants after completing three days of aiTBS when compared against their respective baselines. Intra-therapeutic changes to theta oscillatory signal will also be collected as an additional primary outcome. Averages of theta oscillatory power within each day of aiTBS will be recorded and compared against baseline.
Aim 2 Outcome: Task Performance. Participants will complete both a working memory and affective interference task. The primary outcome measure will be task performance as measured by response time for each subject. Values collected after aiTBS will be compared against their pre-stimulation counterparts using a paired t-test for a given task. The change in these metrics will then be compared across the two tasks using an unpaired t-test. Change in performance metrics for each task will similarly be compared against changes in metrics of the participant group receiving stimulation to the alternate site. We hypothesize performance on network-congruent tasks increase after aiTBS.
Data Analyses. The primary responses will be continuously distributed, and we will compare the active to sham conditions using linear mixed effects models. For the response of Aim 1, we will possibly transform the responses to reduce levels of skewness. When conducting TEP measurements, the order in which participants receive stimulation will be randomly assigned such that 50% of participants receive stimulation to the DLPFC first and 50% receive stimulation to the TPJ first. For the behavioral responses of Aim 2 we will use Fisher's z-transform to symmetrize the distribution and stabilize the variance. The models will include two-level categorical factors for treatment and period; as the period and treatment factors are categorical, these models accommodate arbitrary treatment effects, and, for example, do not assume a linear trend across the treatments. We will include random intercepts for participant and will check whether additional covariance structure is required to account for within-participant correlations. We will also examine treatment by period interaction effects. If these effects are significant, we will report estimated effects and associated standard errors and p-values separately by period; if the interaction effects are non-significant, then we will report estimates of effect pooled over periods.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Nicholas Balderston
- Numero di telefono: 12157463058
- Email: nicholas.balderston@pennmedicine.upenn.edu
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Able to give their consent
- Right-handed or ambidextrous
Exclusion Criteria:
- Non-english speaking
- Current or past non-anxiety-related psychiatric comorbidity.
- Active or history of active suicidal ideation
- Alcohol/drug problems in the past year or lifetime alcohol or drug dependence
- Medications that act on the central nervous system
- History of seizure
- History of epilepsy
- Increased risk of seizure for any reason
- Pregnancy, or positive pregnancy test
- Any medical (e.g., stroke, breathing problems, motion disorders) or neurological (e.g., a significant brain injury or brain infection history that increases seizure risk) condition that increases risk for fMRI or TMS (Protocol will follow recommendations from Rossi et al. 2021 doi:10.1016/j.clinph.2020.10.003)
- Any metal in their body which would make having an MRI scan unsafe
- Any sort of medical implants
- Hearing loss
- Claustrophobia
- orthostatic hypotension
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Scienza basilare
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: dlPFC TMS
Individualized left dlPFC targets will be identified using task-based fMRI activation during the baseline Sternberg.
BOLD activity maps from the retention interval will be masked with a left dlPFC region of interest defined from a group-level analysis of an independent Sternberg dataset.
Activity will be contrasted between sort and maintain conditions, and the peak voxel within this mask will be extracted as the individualized target.
|
aiTBS stimulation parameters.
A MagVenture MagPro 100X stimulator with a B65 figure-8 coil will be used for the aiTBS sessions.
A series of 20, 10 s trains will be presented over the course of the ~3.5 min session.
Each train will consist of 2 s of stimulation with an 8 s ITI.
During the 2 s of stimulation, 10, 50 Hz bursts will be repeated at intervals of 200 ms (5 Hz).
|
|
Sperimentale: TPJ TMS
Individualized left TPJ targets will be identified using task-based fMRI activation during the baseline Sternberg.
BOLD activity maps from the retention interval will be masked with a left TPJ region of interest defined from a group-level analysis of an independent Sternberg dataset.
Activity will be contrasted between sort and maintain conditions, and the peak negative voxel within this mask will be extracted as the individualized target.
|
aiTBS stimulation parameters.
A MagVenture MagPro 100X stimulator with a B65 figure-8 coil will be used for the aiTBS sessions.
A series of 20, 10 s trains will be presented over the course of the ~3.5 min session.
Each train will consist of 2 s of stimulation with an 8 s ITI.
During the 2 s of stimulation, 10, 50 Hz bursts will be repeated at intervals of 200 ms (5 Hz).
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Spectral Dynamics
Lasso di tempo: Participants will undergo six study visits spaced over a 2-week period. Outcome measures will be collected during study visits 2-6 during week 2.
|
All participants will undergo TEP measurements before and after aiTBS therapy (peri-therapeutic) at the left DLPFC and left TPJ to evaluate changes cortical excitability.
We will average the results of repeated single pulse stimulation at an intensity of 120% RMT.
Participants will also undergo scalp EEG recording during aiTBS sessions and while at rest.
Peri-therapeutic oscillatory bands will be determined by averaging responses to across multiple baseline recording sessions using the MATLAB toolbox FieldTrip for detection of signal within the 4-8Hz spectral band.
We hypothesize that theta power increases in participants after completing three days of aiTBS when compared against their respective baselines.
Intra-therapeutic changes to theta oscillatory signal will also be collected as an additional primary outcome.
Averages of theta oscillatory power within each day of aiTBS will be recorded and compared against baseline.
|
Participants will undergo six study visits spaced over a 2-week period. Outcome measures will be collected during study visits 2-6 during week 2.
|
|
Task Performance
Lasso di tempo: Participants will undergo six study visits spaced over a 2-week period. Outcome measures will be collected during study visits 2-6 during week 2.
|
Participants will complete both a working memory and affective interference task.
The primary outcome measure will be task performance as measured by response time for each subject.
Values collected after aiTBS will be compared against their pre-stimulation counterparts using a paired t-test for a given task.
The change in these metrics will then be compared across the two tasks using an unpaired t-test.
Change in performance metrics for each task will similarly be compared against changes in metrics of the participant group receiving stimulation to the alternate site.
We hypothesize performance on network-congruent tasks increase after aiTBS.
|
Participants will undergo six study visits spaced over a 2-week period. Outcome measures will be collected during study visits 2-6 during week 2.
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Nicholas L Balderston, PhD, University of Pennsylvania
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
- 26-6524
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Plasticità cerebrale
-
University of PadovaReclutamentoAnestesia Brain MonitoringItalia
-
University of PadovaCompletato
-
University of PadovaCompletatoPropofol | Anestesia Brain MonitoringItalia
-
University of PadovaCompletato
-
University of PadovaCompletato
-
University of PadovaCompletatoPropofol | Anestesia Brain MonitoringItalia
-
University of PadovaCompletatoLidocaina | Anestesia Brain MonitoringItalia
-
University of PadovaReclutamentoPropofol | Remifentanil | Anestesia Brain MonitoringItalia
-
University of Dublin, Trinity CollegeSconosciutoBrain Health Atleti d'élite in pensione
-
University of EdinburghNHS LothianNon ancora reclutamentoDeterioramento cognitivo | Anestesia | Compromissione cognitiva, lieve | Anestesia Brain Monitoring | Compromissione cognitiva, progressiva | Monitoraggio della profondità dell'anestesiaRegno Unito
Prove cliniche su TBS
-
University of Texas at AustinReclutamentoCompromissione cognitiva lieveStati Uniti
-
Wake Forest University Health SciencesCompletatoMal di schiena | Dolore cronico | Dolore neuropatico | Uso di oppioidi | Dolore, cronico | Dipendenza da oppiacei | Neuropatia periferica indotta da chemioterapia | Mal di schiena cronicoStati Uniti
-
Stanford UniversityCompletatoDepressione resistente al trattamentoStati Uniti
-
Northwestern UniversityNational Institute of Mental Health (NIMH)ReclutamentoComportamento di avvicinamento/evitamentoStati Uniti
-
RenJi HospitalNon ancora reclutamento
-
Stanford UniversityAttivo, non reclutanteDepressione resistente al trattamentoStati Uniti
-
QualissimaPharmacog's project (IMI)Terminato
-
University Hospital, CaenSconosciutoCognizione sociale nei pazienti con schizofreniaFrancia
-
Stanford UniversityCompletatoDepressione resistente al trattamentoStati Uniti
-
University of ArizonaNational Institute on Aging (NIA)CompletatoCompromissione cognitiva lieveStati Uniti